MSFT   214.46 (+0.77%)
FB   243.77 (+0.08%)
GOOGL   1,522.32 (+1.25%)
AMZN   3,129.97 (+1.59%)
NVDA   416.97 (+2.04%)
CGC   16.03 (-1.84%)
AMD   55.83 (+4.49%)
DIS   117.04 (+0.33%)
BAC   22.75 (-1.52%)
MSFT   214.46 (+0.77%)
FB   243.77 (+0.08%)
GOOGL   1,522.32 (+1.25%)
AMZN   3,129.97 (+1.59%)
NVDA   416.97 (+2.04%)
CGC   16.03 (-1.84%)
AMD   55.83 (+4.49%)
DIS   117.04 (+0.33%)
BAC   22.75 (-1.52%)
MSFT   214.46 (+0.77%)
FB   243.77 (+0.08%)
GOOGL   1,522.32 (+1.25%)
AMZN   3,129.97 (+1.59%)
NVDA   416.97 (+2.04%)
CGC   16.03 (-1.84%)
AMD   55.83 (+4.49%)
DIS   117.04 (+0.33%)
BAC   22.75 (-1.52%)
MSFT   214.46 (+0.77%)
FB   243.77 (+0.08%)
GOOGL   1,522.32 (+1.25%)
AMZN   3,129.97 (+1.59%)
NVDA   416.97 (+2.04%)
CGC   16.03 (-1.84%)
AMD   55.83 (+4.49%)
DIS   117.04 (+0.33%)
BAC   22.75 (-1.52%)
Log in

Piper Sandler Reaffirms Market Perform Rating for Fluidigm (NASDAQ:FLDM)

Last updated on Thursday, July 9, 2020 | 2020 MarketBeat

Fluidigm (NASDAQ:FLDM)'s stock had its "market perform" rating reiterated by equities researchers at Piper Sandler in a research report issued on Thursday, AnalystRatings.com reports. They presently have a $9.00 price target on the medical research company's stock. Piper Sandler's target price suggests a potential upside of 58.45% from the stock's previous close.

Several other analysts have also recently commented on FLDM. BTIG Research reissued a "buy" rating and issued a $12.00 price target on shares of Fluidigm in a report on Thursday. Zacks Investment Research raised Fluidigm from a "sell" rating to a "hold" rating in a report on Tuesday. Three research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Fluidigm currently has a consensus rating of "Buy" and an average target price of $8.00.

FLDM stock opened at $5.68 on Thursday. The stock has a market capitalization of $309.34 million, a PE ratio of -7.10 and a beta of 2.05. The company has a fifty day moving average of $4.12 and a 200-day moving average of $3.43. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.87 and a current ratio of 2.33. Fluidigm has a one year low of $1.17 and a one year high of $12.26.

Fluidigm (NASDAQ:FLDM) last posted its quarterly earnings results on Thursday, May 7th. The medical research company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.09). Fluidigm had a negative return on equity of 23.20% and a negative net margin of 48.20%. The firm had revenue of $27.62 million for the quarter. Equities analysts forecast that Fluidigm will post -0.53 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of FLDM. Swiss National Bank grew its holdings in Fluidigm by 5.1% in the first quarter. Swiss National Bank now owns 134,900 shares of the medical research company's stock valued at $343,000 after purchasing an additional 6,600 shares during the last quarter. Prudential Financial Inc. acquired a new position in shares of Fluidigm during the 4th quarter worth $108,000. Citigroup Inc. boosted its position in shares of Fluidigm by 131.7% in the 4th quarter. Citigroup Inc. now owns 14,243 shares of the medical research company's stock worth $50,000 after buying an additional 8,095 shares in the last quarter. Barclays PLC grew its stake in Fluidigm by 38.0% in the 4th quarter. Barclays PLC now owns 69,275 shares of the medical research company's stock valued at $241,000 after acquiring an additional 19,077 shares during the last quarter. Finally, Alyeska Investment Group L.P. purchased a new position in Fluidigm during the 4th quarter valued at about $3,905,000. Institutional investors own 89.79% of the company's stock.

About Fluidigm

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.

Further Reading: How to interpret Moving Average Convergence Divergence (MACD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Restaurant Stocks That Still Look Tasty As the Economy Reopens

As part of our national response to the Covid-19 pandemic, many Americans considered it their patriotic, if not moral, duty to support the restaurant industry. And while many consumers were intensely focused on their small, local restaurants, the national chains were still open for business during this time.

And the reality is that the national chains are going to be the most adaptable to whatever pace of economic recovery we see. Hopes for a “V” shaped recovery have pretty much gone out the window. The new model suggests a stair-step recovery may be the best-case scenario.

The worst case scenario for the restaurant industry will be one where different regions of the country are subject to rolling lockdowns. In a business with notoriously low margins, an open/close, open/close recovery would be disastrous.

It’s one reason why I’m not sure I would be diving into restaurant stocks right now. But the same was being said of airline stocks and cruise line stocks. And sure enough, discount investors have been trying to invest in these stocks.

But as all 50 states have now re-opened in some fashion, it’s not unlikely that restaurant stocks are drawing attention from investors. We’ve put together this presentation that highlights seven restaurant stocks that you should consider looking at if you want to dive into this sector.

View the "Restaurant Stocks That Still Look Tasty As the Economy Reopens".

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.